EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis

Andrew Mihalache, Amin Hatamnejad, Nikhil S Patil, Marko M Popovic, Peter J Kertes, Miguel Cruz-Pimentel, Rajeev H Muni

Ophthalmologica · 2024 · 247 (1) · 19-29

DOI: 10.1159/000533443 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Ophthalmologica, online erschienen am 14.08.2023. Verfasst von Andrew Mihalache und 6 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, andrewmihalache02@gmail.com. Hauptthemen laut MEDLINE: Macular Edema, Retinal Vein Occlusion, Intravitreal Injections, Diabetic Retinopathy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The comparative safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular edema (DME) and macular edema (ME) secondary to retinal vein occlusion (RVO) is unclear.

Objectives

This meta-analysis aimed to compare the safety and efficacy of different doses of IVTA in this setting.

Methods

A systematic literature search for randomized clinical trials (RCTs) was conducted on Cochrane Library, Ovid MEDLINE, and EMBASE from January 2005 to May 2022. Studies that reported on patients with DME or ME secondary to RVO that received treatment with different doses of IVTA were included. A random-effects meta-analysis was performed. Cochrane’s Risk of Bias Tool 2 was used to assess the risk of bias, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidelines were used to assess certainty of evidence.

Results

Five RCTs reporting on 1,041 eyes at baseline were included in this meta-analysis. In eyes with ME secondary to RVO, high-dose (4 mg) IVTA achieved a significantly better change in best-corrected visual acuity (WMD = −4.75 ETDRS letters, 95% CI = [−7.73, −1.78], p = 0.002) and reduction in retinal thickness (WMD = −93.02 μm, 95% CI = [−153.23, −32.82], p = 0.002) at months 4–6 compared to low-dose (1–2 mg) IVTA. However, high-dose IVTA had a higher risk of intraocular pressure-related adverse events (RR = 2.99, 95% CI = [1.05, 8.50], p = 0.04) and cataract surgery (RR = 5.67, 95% CI = [3.09, 10.41], p < 0.00001) than low-dose IVTA in eyes with ME secondary to RVO. These efficacy and safety differences in high-dose and low-dose IVTA were not observed in DME eyes.

Conclusions

The RCT evidence in this setting is limited. High-dose IVTA achieved greater improvements in visual acuity and reductions in retinal thickness than low-dose IVTA at months 4–6. However, high-dose IVTA had a less favorable safety profile than low-dose IVTA. The significance of these outcomes was based on patients with ME secondary to RVO, but not DME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaRetinal Vein OcclusionIntravitreal InjectionsDiabetic RetinopathyTriamcinolone AcetonideGlucocorticoidsVisual AcuityHumansTomography, Optical CoherenceTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Diabetic macular edemaRetinal vein occlusionTriamcinolone acetonide

Substanzen

Triamcinolone AcetonideGlucocorticoids

Autor:innen und Institutionen

  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, andrewmihalache02@gmail.com.
  • Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
  • John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada.

Zitieren

APA

Mihalache, A., Hatamnejad, A., Patil, N. S., Popovic, M. M., Kertes, P. J., Cruz-Pimentel, M., & Muni, R. H. (2024). Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis. Ophthalmologica, 247(1), 19-29. https://doi.org/10.1159/000533443

Vancouver

Mihalache A, Hatamnejad A, Patil NS, Popovic MM, Kertes PJ, Cruz-Pimentel M, et al. Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis. Ophthalmologica. 2024;247(1):19-29. doi:10.1159/000533443

BibTeX
@article{Mihalache2024,
  author = {Mihalache, Andrew and Hatamnejad, Amin and Patil, Nikhil S and Popovic, Marko M and Kertes, Peter J and Cruz-Pimentel, Miguel and Muni, Rajeev H},
  title = {Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis},
  journal = {Ophthalmologica},
  year = {2024},
  volume = {247},
  number = {1},
  pages = {19--29},
  doi = {10.1159/000533443}
}
Kostenlos starten →